bevacizumab + cetuximab + gefitinib

This is an experimental combination therapy consisting of three targeted agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) in tumors. - **Cetuximab** is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting its activation and downstream signaling involved in tumor cell proliferation and survival. - **Gefitinib** is a small molecule tyrosine kinase inhibitor that selectively inhibits the EGFR tyrosine kinase domain, blocking signal transduction pathways implicated in cancer cell growth. The rationale for combining these agents lies in dual inhibition of EGFR signaling (by both cetuximab and gefitinib) alongside anti-angiogenic therapy with bevacizumab. This approach aims to overcome resistance mechanisms to single-agent EGFR inhibitors by simultaneously targeting VEGF-mediated pathways. While similar combinations have been studied—such as dual EGFR inhibition with erlotinib plus cetuximab together with bevacizumab—there are no published clinical trials specifically evaluating the triple combination of bevacizumab, cetuximab, and gefitinib. The closest analogs suggest this regimen would be considered investigational or experimental for advanced solid tumors such as metastatic colorectal cancer or non-small cell lung cancer[1][5][7].

Other names

bevacizumab and cetuximab and gefitinibbevacizumab/cetuximab/gefitinib combination